Panitumumab( —— )

Catalog No. M22158 CAS No. 339177-26-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Panitumumab
Note

Research use only, not for human use.
Brief Description

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
Description

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
In Vitro

Western Blot Analysis Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells Concentration:2, 20, 200, 2000 nM Incubation Time:3 h Result:Inhibited ligand-induced autophosphorylation of EGFR.
In Vivo

Animal Model:NCI-H1975 and NCI-H1650 xenografts Dosage:25, 100, or 500 μg/mouse Administration:Intraperitoneal injection (i.p.), twice a week Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
Synonyms

——
Pathway

Angiogenesis
Target

EGFR
Recptor

EGFR
Research Area

——
Indication

——

1. Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan;18(1):7-15.

Calculator

molnova catalog